[ad_1]
The pharmaceutical company AstraZeneca, which jointly developed a coronavirus vaccine with the University of Oxford, had to explain after it was discovered that they had made mistakes when testing the product, and this was only noticed after they wrote vegetables in the advertisement for the vaccine.
AstraZeneca and the University of Oxford have acknowledged that they have tested some of their coronavirus vaccines at the wrong dose, raising questions among some health experts about how reliable the drug is, reveals the Business Insider article.
Perhaps even more embarrassing is that the bug was discovered only after the pharmaceutical manufacturer issued a confusing announcement about the test results.
According to the erroneous report, their vaccination has an average effectiveness of 70 percent, which means that subjects who received two full-dose injections of the two-dose vaccine developed a reliable protection of 62 percent, while those who received only half of the first injection received 90 percent protection. The result was achieved. As it turned out, in tests involving the British, some of the subjects accidentally received half the dose. This is the basis of communication on vegetables.
Dubious experts
The experts, of course, immediately began to suspect how they could achieve better results than those who had not received the full amount of vaccine, and I see that they were right. The AstraZeneca report revealed that half the dose was administered to 2,800 testers, while 8,900 received the full treatment.
It was also found that the test subjects who received half the dose for the first puncture were generally not older than 55 years. As the younger immune system responds better to vaccines, this may explain why the vaccine has been shown to be effective at lower doses.
However, the communication, which it was intended to clarify, failed to clear up the doubts of the external experts, and some even said that it raised more questions than it solved, at least about the thoroughness and transparency of the tests carried out by the AstraZeneca-University couple from Oxford. Furthermore, it is doubtful whether the formulation is actually particularly good for the elderly, as previously stated by the parties.
[ad_2]
